Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment

Adam M. Brufsky, MD, PhD
Published: Thursday, Jun 29, 2017



Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.

In the neoadjuvant setting, using CDK 4/6 inhibitors with hormonal therapy is in the future of breast cancer treatment, particularly with luminal A tumors.

Response trials are currently ongoing that may guide in the decision to use CDK 4/6 inhibitors in this setting.
 


Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.

In the neoadjuvant setting, using CDK 4/6 inhibitors with hormonal therapy is in the future of breast cancer treatment, particularly with luminal A tumors.

Response trials are currently ongoing that may guide in the decision to use CDK 4/6 inhibitors in this setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x